PT3444349T - Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos - Google Patents
Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãosInfo
- Publication number
- PT3444349T PT3444349T PT181837352T PT18183735T PT3444349T PT 3444349 T PT3444349 T PT 3444349T PT 181837352 T PT181837352 T PT 181837352T PT 18183735 T PT18183735 T PT 18183735T PT 3444349 T PT3444349 T PT 3444349T
- Authority
- PT
- Portugal
- Prior art keywords
- organs
- compositions
- methods
- reperfusion injury
- ischemia reperfusion
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000000056 organ Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004239P | 2014-05-29 | 2014-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3444349T true PT3444349T (pt) | 2021-04-06 |
Family
ID=53398201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181837352T PT3444349T (pt) | 2014-05-29 | 2015-05-27 | Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos |
| PT15729289T PT3149172T (pt) | 2014-05-29 | 2015-05-27 | Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15729289T PT3149172T (pt) | 2014-05-29 | 2015-05-27 | Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20170081665A1 (enExample) |
| EP (2) | EP3149172B1 (enExample) |
| JP (2) | JP2017521374A (enExample) |
| KR (1) | KR20170007492A (enExample) |
| CN (2) | CN112410336A (enExample) |
| AU (1) | AU2015267160B2 (enExample) |
| BR (1) | BR112016028009A2 (enExample) |
| CA (1) | CA2949109A1 (enExample) |
| DK (2) | DK3149172T3 (enExample) |
| ES (2) | ES2862185T3 (enExample) |
| HU (2) | HUE040092T2 (enExample) |
| IL (2) | IL248912A0 (enExample) |
| LT (2) | LT3149172T (enExample) |
| MX (2) | MX373950B (enExample) |
| PL (2) | PL3444349T3 (enExample) |
| PT (2) | PT3444349T (enExample) |
| SI (2) | SI3444349T1 (enExample) |
| WO (1) | WO2015183842A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US12091664B2 (en) | 2018-01-12 | 2024-09-17 | University Of Massachusetts | Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation |
| GB202016863D0 (en) * | 2020-10-23 | 2020-12-09 | Causeway Therapeutics Ltd | Microrna-29 compounds, compositions and uses in therapy |
| AU2022418939A1 (en) * | 2021-12-22 | 2024-03-21 | Na Vaccine Institute | Composition for preventing or treating ischemia-reperfusion injury and use thereof |
| KR20240154159A (ko) * | 2023-04-17 | 2024-10-25 | 재단법인 아산사회복지재단 | miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물 |
| CN118460648B (zh) * | 2024-07-10 | 2025-01-28 | 凯莱英医药集团（天津）股份有限公司 | 一种qpi-1002的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| WO2000044364A2 (en) | 1999-01-29 | 2000-08-03 | The Board Of Trustees Of The University Of Illinois | P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| US20060105975A1 (en) | 2004-04-19 | 2006-05-18 | Shannon Pendergrast | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
| JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| US8362229B2 (en) | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| CA2701845A1 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| WO2009155504A2 (en) * | 2008-06-20 | 2009-12-23 | The Children's Medical Center Corporation | Methods for the modulation of angiogenesis |
| US8637482B2 (en) * | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| JPWO2011138966A1 (ja) | 2010-05-06 | 2013-07-22 | ダイヤニトリックス株式会社 | 微生物触媒を用いたアクリルアミドの製造方法 |
| US9808461B2 (en) * | 2010-11-17 | 2017-11-07 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
| EP2649181B1 (en) | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| US9176487B2 (en) * | 2011-10-24 | 2015-11-03 | Mayo Foundation For Medical Education And Research | Methods and materials for reducing the risk of infections |
| ES2704855T3 (es) * | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
-
2015
- 2015-05-27 SI SI201531563T patent/SI3444349T1/sl unknown
- 2015-05-27 EP EP15729289.7A patent/EP3149172B1/en not_active Not-in-force
- 2015-05-27 KR KR1020167037012A patent/KR20170007492A/ko not_active Withdrawn
- 2015-05-27 US US15/312,425 patent/US20170081665A1/en not_active Abandoned
- 2015-05-27 HU HUE15729289A patent/HUE040092T2/hu unknown
- 2015-05-27 CA CA2949109A patent/CA2949109A1/en not_active Abandoned
- 2015-05-27 PT PT181837352T patent/PT3444349T/pt unknown
- 2015-05-27 SI SI201530342T patent/SI3149172T1/sl unknown
- 2015-05-27 LT LTEP15729289.7T patent/LT3149172T/lt unknown
- 2015-05-27 DK DK15729289.7T patent/DK3149172T3/en active
- 2015-05-27 EP EP18183735.2A patent/EP3444349B1/en active Active
- 2015-05-27 LT LTEP18183735.2T patent/LT3444349T/lt unknown
- 2015-05-27 WO PCT/US2015/032499 patent/WO2015183842A1/en not_active Ceased
- 2015-05-27 PL PL18183735T patent/PL3444349T3/pl unknown
- 2015-05-27 CN CN202011264844.9A patent/CN112410336A/zh active Pending
- 2015-05-27 MX MX2016015635A patent/MX373950B/es active IP Right Grant
- 2015-05-27 BR BR112016028009A patent/BR112016028009A2/pt active Search and Examination
- 2015-05-27 PT PT15729289T patent/PT3149172T/pt unknown
- 2015-05-27 CN CN201580041391.4A patent/CN106661579B/zh not_active Expired - Fee Related
- 2015-05-27 ES ES18183735T patent/ES2862185T3/es active Active
- 2015-05-27 HU HUE18183735A patent/HUE054226T2/hu unknown
- 2015-05-27 PL PL15729289T patent/PL3149172T3/pl unknown
- 2015-05-27 ES ES15729289.7T patent/ES2683869T3/es active Active
- 2015-05-27 JP JP2016569875A patent/JP2017521374A/ja not_active Withdrawn
- 2015-05-27 DK DK18183735.2T patent/DK3444349T3/da active
- 2015-05-27 AU AU2015267160A patent/AU2015267160B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 IL IL248912A patent/IL248912A0/en active IP Right Grant
- 2016-11-28 MX MX2020005794A patent/MX2020005794A/es unknown
-
2017
- 2017-07-14 US US15/650,297 patent/US9868953B2/en active Active
- 2017-12-05 US US15/832,334 patent/US20180305696A1/en not_active Abandoned
-
2020
- 2020-04-20 JP JP2020074549A patent/JP2020128383A/ja active Pending
- 2020-10-19 IL IL278144A patent/IL278144B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2535253B (en) | Compositions and methods | |
| GB2534873B (en) | Improvements in and relating to horseshoes | |
| IL278144B (en) | Compositions for the prevention of organ damage resulting from ischemia-reperfusion | |
| IL246879A0 (en) | Preparations of Epilimod and methods of using them | |
| GB201522204D0 (en) | Improvements in or relating to clamping devices | |
| PT3220908T (pt) | Composições e métodos para o tratamento da endometriose | |
| ZA201605109B (en) | Compositions and methods for treating neutropenia | |
| IL264760B1 (en) | Regional ischemia/reperfusion injury | |
| GB201518802D0 (en) | Improvements in and relating to nozzles | |
| EP3104896A4 (en) | Compositions and methods for treating liver injury | |
| GB201401373D0 (en) | Compositions for cells lysis and uses thereof | |
| IL246637A0 (en) | Preparations and methods for the treatment of intracerebral hemorrhage | |
| PT3160263T (pt) | Composições para prevenção de infeções | |
| GB201402915D0 (en) | Compositions and methods | |
| GB2530075B (en) | Improvements in and relating to eyewashing | |
| PT3210628T (pt) | Métodos para complexos de frutoborato | |
| PL2990058T3 (pl) | Ulepszone kompozycje i sposoby dla kompleksów fruktoboranowych | |
| GB201509274D0 (en) | Improvements in agricultural equipment | |
| GB201704057D0 (en) | Improvements in agricultural equipment | |
| GB201417432D0 (en) | Improvements in and relating to pipe-breaking | |
| GB201403212D0 (en) | Compositions and methods | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| HUE038776T2 (hu) | Szinergikus felületaktív anyag összetétel | |
| GB201412345D0 (en) | Improvements in and relating to devices | |
| GB201404831D0 (en) | Animalistic studies in nature |